A randomized, double-blind, placebo-controlled pilot trial of safety and tolerability of two doses of divalproex sodium in outpatients with probable Alzheimer's disease

Current Alzheimer Research

Volumn 2, Issue 5, 2005, Pages 553-558

  Profenno, Louis A ^a   Jakimovich, Laura ^a   Holt, Connie J ^a   Porsteinsson, Anton ^a   Tariot, Pierre N ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Alzheimer's disease; Divalproex; Neuroprotection; Tolerability; Valproic acid

Indexed keywords

PLACEBO; VALPROATE SEMISODIUM;

AGED; AGITATION; ALZHEIMER DISEASE; ARTICLE; ATTENTION DEFICIT DISORDER; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; COMMON COLD; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DELAYED RELEASE FORMULATION; DIARRHEA; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DYSPHAGIA; EATING DISORDER; FALLING; FATIGUE; FEMALE; FLUID INTAKE; FUNCTIONAL ASSESSMENT; GAIT DISORDER; HUMAN; LABORATORY TEST; LACRIMAL GLAND DISEASE; MALE; MEMORY DISORDER; MINI MENTAL STATE EXAMINATION; MUSCLE CRAMP; NAUSEA; NIGHTMARE; NURSING HOME; OUTPATIENT; PILOT STUDY; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; RANK SUM TEST; SIDE EFFECT; SOMNOLENCE; SPEECH DISORDER; TASK PERFORMANCE; TREMOR;

EID: 28244475064     PISSN: 15672050     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720505774932205     Document Type: Article

References (20)

1. Tariot PN, Loy R, Ryan JM, et al. Mood stabilizers in Alzheimer's disease: symptomatic and neuroprotective rationales. Adv Drug Deliv Rev. 54:1567-77 (2002).
2. Profenno LA and Tariot PN. Pharmacologic management of agitation in Alzheimer's disease. Dement Geriatr Cogn Disord. 17:65-77 (2004).
3. Chen G, Huang LD, Jiang YM, Manji HK. The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3. J Neurochem. 72:1327-30 (1999).
4. Freitag FG, Collins SD, Carlson HA, et al., Depakote ER Migraine Study Group. A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis. Neurology 58:1652-9 (2002).
5. Thibault M, Blume WT, Saint-Hilaire JM, et al. Divalproex extended-release versus the original divalproex tablet: results of a randomized, crossover study of well-controlled epileptic patients with primary generalized seizures. Epilepsy Res. 50:243-9 (2002).
6. Freitag FG. Divalproex sodium extended-release for the prophylaxis of migraine headache. Expert Opin Pharmacother. 4:1573-8 (2003).
7. Home RL and Cunanan C. Safety and efficacy of switching psychiatric patients from a delayed-release to an extended-release formulation of divalproex sodium. J Clin Psychopharmacol. 23:176-81 (2003).
8. Porsteinsson AP, Tariot PN, Erb R, et al. Placebo-controlled study of divalproex sodium for agitation in dementia. Am J Geriatr Psychiatry 9:58-66 (2001).
9. Porsteinsson AP, Tariot PN, Jakimovich LJ, et al. Valproate therapy for agitation in dementia: open-label extension of a double-blind trial. Am J Geriatr Psychiatry 11:434-40 (2003).
10. Cummings JL, Mega M, Gray K, et al. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 44:2308-14 (1994).
11. Dutta S, Zhang Y, Selness DS, et al. Comparison of the bioavailability of unequal doses of divalproex sodium extended-release formulation relative to the delayed-release formulation in healthy volunteers. Epilepsy Res. 49:1-10 (2002).
12. Folstein MF, Folstein SE, McHugh PR. "Mini-Mental State": a practical method for grading the cognitive state of patients by the clinician. J Psychiatr Res. 12:189-198 (1975).
13. Lawton MP and Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 9:179-186 (1969).
14. Guy W, (ed.) ECDEU Assessment Manual for Psychopharmacology revised. Rockville, MD, National Institute of Mental Health (1976).
15. Miller MD, Paradis CF, Houck PR, et al. Rating chronic medical illness burden in geropsychiatric practice and research: application of the Cumulative Illness Rating Scale. Psychiatry Res. 41:237-48 (1992).
16. Centorrino F, Kelleher JP, Berry JM, el at. Pilot comparison of extended-release and standard preparations of divalproex sodium in patients with bipolar and schizoaffective disorders. Am J Psychiatry 160:1348-50 (2003).
17. Sival RC, Haffmans PM, Jansen PA, et al. Sodium valproate in the treatment of aggressive behavior in patients with dementia-a randomized placebo controlled clinical trial. Int J Geriatr Psychiatry 17:579-85 (2002).
18. Tariot PN, Schneider L, Mintzer J, et al. Safety and Tolerability of Divalproex Sodium for the Treatment of Signs and Symptoms of Mania in Elderly Patients with Dementia: Results of a Double-Blind, Placebo-Controlled Trial. Current Therapeutic Research 62:51-67 (2001).
19. Federoff H, Mhyre T, Loy R, Coleman P, Profenno L, Casaceli C, Maguire-Zeiss K, Zhang D, Tariot P (Poster Presentation): "Proteomic Analysis of Peripheral Leukocyte Biomarkers in Alzheimer's Disease Patients Treated with Divalproex Sodium." International Congress on Alzheimer's Disease, Philadelphia, Pennsylvania, July 2004
20. Coleman PD, Delvaux E, Colt L, Tariot P, Loy R, Johnson E, Casaceli C, Federoff H. (Poster Presentation): "Transcriptomic Analysis of Peripheral Leukocyte Biomarkers in Valproate Treated Cultured Leukocytes from Alzheimer's Disease Cases." International Congress on Alzheimer's Disease, Philadelphia, Pennsylvania, July 2004